WINTON GROUP Ltd Purchases Shares of 18,479 Elanco Animal Health Incorporated (NYSE:ELAN)

WINTON GROUP Ltd bought a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 18,479 shares of the company’s stock, valued at approximately $267,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Envestnet Asset Management Inc. boosted its stake in shares of Elanco Animal Health by 125.1% during the 2nd quarter. Envestnet Asset Management Inc. now owns 119,655 shares of the company’s stock worth $1,727,000 after acquiring an additional 66,503 shares during the period. Oppenheimer Asset Management Inc. boosted its stake in shares of Elanco Animal Health by 51.2% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 18,291 shares of the company’s stock worth $264,000 after acquiring an additional 6,191 shares during the period. O Neil Global Advisors Inc. bought a new position in shares of Elanco Animal Health during the 2nd quarter worth approximately $163,000. HBK Sorce Advisory LLC boosted its stake in shares of Elanco Animal Health by 9.4% during the 2nd quarter. HBK Sorce Advisory LLC now owns 12,920 shares of the company’s stock worth $186,000 after acquiring an additional 1,107 shares during the period. Finally, Federated Hermes Inc. boosted its stake in shares of Elanco Animal Health by 1.5% during the 2nd quarter. Federated Hermes Inc. now owns 2,066,277 shares of the company’s stock worth $29,816,000 after acquiring an additional 30,434 shares during the period. 97.48% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, CEO Jeffrey N. Simmons purchased 100,000 shares of the stock in a transaction dated Monday, August 12th. The stock was bought at an average price of $13.01 per share, with a total value of $1,301,000.00. Following the acquisition, the chief executive officer now owns 145,000 shares of the company’s stock, valued at $1,886,450. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Elanco Animal Health news, Director Michael J. Harrington purchased 3,500 shares of the stock in a transaction dated Thursday, August 22nd. The stock was bought at an average price of $14.85 per share, with a total value of $51,975.00. Following the acquisition, the director now owns 81,094 shares of the company’s stock, valued at $1,204,245.90. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jeffrey N. Simmons purchased 100,000 shares of the stock in a transaction dated Monday, August 12th. The shares were acquired at an average cost of $13.01 per share, with a total value of $1,301,000.00. Following the acquisition, the chief executive officer now directly owns 145,000 shares in the company, valued at approximately $1,886,450. The disclosure for this purchase can be found here. Insiders own 0.57% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on ELAN. Piper Sandler reduced their price target on Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating for the company in a research note on Monday, July 1st. Barclays reduced their price target on Elanco Animal Health from $23.00 to $21.00 and set an “overweight” rating for the company in a research note on Friday, June 28th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $17.57.

Elanco Animal Health Price Performance

Shares of NYSE ELAN opened at $14.65 on Thursday. The stock has a market capitalization of $7.24 billion, a PE ratio of -5.53, a P/E/G ratio of 1.44 and a beta of 1.40. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.93 and a quick ratio of 1.75. The business has a fifty day moving average price of $13.89 and a two-hundred day moving average price of $15.17. Elanco Animal Health Incorporated has a fifty-two week low of $8.52 and a fifty-two week high of $18.80.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.06. The firm had revenue of $1.18 billion during the quarter, compared to analysts’ expectations of $1.15 billion. Elanco Animal Health had a positive return on equity of 7.29% and a negative net margin of 27.94%. The company’s quarterly revenue was up 12.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.18 EPS. As a group, equities analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.